Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:2641-2647.
Banerjee A, Jakacki R, Onar-Thomas A, et al. A phase 1 study of AZD6244 in children with recurrent or refractory low grade gliomas: a pediatric brain tumor consortium report. Poster presented at: ASCO^® 2014 Annual Meeting; May 30-June 3, 2014; Chicago, IL. Poster 10065.
Bendell JC, Javle M, Bekaii-Saab TS, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017;116:575-583.
Bhatia S, Chen Y, Wong L, et al. Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1. J Clin Oncol. 2019;37:3050-3058.
Clinicaltrials.gov. Phase II study of binimetinib in children and adults with NF1 plexiform neurofibromas (NF108-BINI). https://clinicaltrials.gov/ct2/show/NCT03231306. Accessed March 24, 2020.
ClinicalTrials.gov. Vinblastine +/- bevacizumab in children with unresectable or progressive low grade glioma (LGG). https://clinicaltrials.gov/ct2/show/NCT02840409. Accessed March 24, 2020.
ClinicalTrials.gov. A study of the drugs selumetinib verus carboplatin/vincristine in patients with neurofibromatosis and low-grade glioma. https://clinicaltrials.gov/ct2/show/NCT03871257. Accessed March 24, 2020.
Cotellic® (cobimetinib) [prescribing information]. South San Francisco, CA; Genentech, Inc; Approved 2015. Revised January 2018.
Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550-2560.
Fangusaro J, Onar-Thomas A, Poussaint TY, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicenter, phase 2 trial. Lancet Oncol. 2019;20:1011-1022.
Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genetics. 2007;44:81-88.
Freret ME, Gutmann DH. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. J Neuro Res. 2019; 97:45-56.
Gross AM, Wolters, PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020. [Epub ahead of print] doi: 10.1056/NEJMoa1912735.
Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20:1643-1651.
Jakacki RI, Dombi E, Steinberg SM, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017;19:289-297.
Jones DT, Kieran MW, Bouffet E, et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20:160-173.
Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017;7429697.
Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333-340.
Mahdi J, Shah AC, Sato A, et al. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology. 2017;88:1584-1589.
McCowage GB, Mueller S, Pratilas C, et al. Trametinib in pediatric patients with neurofibromatosis type 1-associated plexiform neurofibroma: a phase I/II study. Presented at ASCO® 2018 Annual Meeting; June 1-8, 2018; Chicago, IL. Presentation 10504.
Mekinist® (trametinib) [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; Approved 2013. Revised October, 2019
Mektovi® (binimetinib) [prescribing information]. Boulder, CO; Array BioPharma Inc; Approved 2018. Revised January 2019.
Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143:e20190660.
National Center for Biotechnology Information website. Genome Decoration Page. https://www.ncbi.nlm.nih.gov/genome/tools/gdp. Accessed March 24, 2020.
Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52:791-795.
Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11:850-856.
Perreault S, Larouche V, Tabori U, et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activiation of the MAPK/ERK pathway: TRAM-01. BMC Cancer. 2019;19:1250.
Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118:1739-1749.
Robertson KA, Nalepa G, Yang F-C, et al. Pilor phase II trial of imatinib mesylate in neurofibromatosis type 1 patients with plexiform neurofibromas. Lancet Oncol. 2012;13:1218-1224.
Rosen LS, LoRusso P, Ma WW, et al. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016;34:604-613.
Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:671-682.
Wei J, Freytag M, Schober Y, et al. Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo. PLOS One. 2014;9:e107760.
Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17:596-603.
Weiss B, Plotkin S, Widemann B, et al. NF106: phase 2 trial of the MEK inhibitor PD-0325901 in adolescents and adults with NF1-related plexiform neurofibromas: an NF clinical trials consortium study. Neuro Oncol. 2018;20: Abstract NFM-06.
Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61:1598-1602.
Widemann BC, Dombi E, Gillespie A, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014;16:707-718.
Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576-1583.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

David H. Gutmann, MD, PhD

Donald O. Schnuck Family Professor
Vice Chair for Research Affairs
Department of Neurology
Director, Neurofibromatosis Center
Washington University School of Medicine
St. Louis, Missouri

Disclosures

Disclosure: David H. Gutmann, MD, PhD, has disclosed the following relevant financial relationships:
Other: GFAP-Cre mouse licensing to the Tuberous Sclerosis Alliance

Roger J. Packer, MD

Senior VP of Neuroscience and Behavior Medicine
Director, Gilbert Family NF1 Institute
Director, Brain Tumor Institute
Children's National Hospital
Washington, DC

Disclosures

Disclosure: Roger J. Packer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Novartis

Editor

Elaine Hamarstrom, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Will MEK Inhibitors Change the Future Paradigm of NF1?

Authors: David H. Gutmann, MD, PhD; Roger J. Packer, MD
CME / ABIM MOC Released: 3/31/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/31/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for physicians who provide care for patients with neurofibromatosis.

The goal of this activity is for clinicians to be more knowledgeable about emerging clinical trial data on the use of mitogen-extracellular activated protein kinase (MEK) inhibitors for the treatment of neurofibromatosis type 1 (NF1)-related tumors.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Mechanism of action of MEK inhibitors
- Efficacy and safety data from clinical trials of MEK inhibitors for the treatment of NF1-related tumors
Demonstrate greater confidence in their ability to
- Explain the clinical implications of data from clinical trials of MEK inhibitors in the treatment of NF1-related tumors

Disclosures

Faculty

David H. Gutmann, MD, PhD

Donald O. Schnuck Family Professor
Vice Chair for Research Affairs
Department of Neurology
Director, Neurofibromatosis Center
Washington University School of Medicine
St. Louis, Missouri

Disclosures

Disclosure: David H. Gutmann, MD, PhD, has disclosed the following relevant financial relationships:
Other: GFAP-Cre mouse licensing to the Tuberous Sclerosis Alliance

Roger J. Packer, MD

Senior VP of Neuroscience and Behavior Medicine
Director, Gilbert Family NF1 Institute
Director, Brain Tumor Institute
Children's National Hospital
Washington, DC

Disclosures

Disclosure: Roger J. Packer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Novartis

Editor

Elaine Hamarstrom, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and Society for Neuro-Oncology.

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Pediatrics

CME / ABIM MOC

Will MEK Inhibitors Change the Future Paradigm of NF1?

Authors: David H. Gutmann, MD, PhD; Roger J. Packer, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 3/31/2020

Valid for credit through: 3/31/2021, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to improve knowledge related to mitogen-extracellular activated protein kinase kinase (MEK) inhibitors and their role in the treatment of neurofibromatosis type 1 (NF1)-related tumors.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

David H. Gutmann, MD, PhD

Roger J. Packer, MD

Editor

Elaine Hamarstrom, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Will MEK Inhibitors Change the Future Paradigm of NF1?

Target Audience and Goal Statement

Disclosures

Faculty

David H. Gutmann, MD, PhD

Roger J. Packer, MD

Editor

Elaine Hamarstrom, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Will MEK Inhibitors Change the Future Paradigm of NF1?

Educational Impact Challenge